ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR115

Clinical, Angiogenic, and Immune System Markers Predict Preeclampsia in Women with CKD During Pregnancy

Session Information

Category: Women’s Health and Kidney Diseases

  • 2000 Women’s Health and Kidney Diseases


  • Sarween, Nadia, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Hodson, James, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Knox, Ellen M., Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
  • Drayson, Mark Trehane, University of Birmingham, Birmingham, United Kingdom
  • Lipkin, Graham W., University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

Pre-eclampsia (PE) is associated with immune activation and altered circulating angiogenic factors (with elevated soluble FMS-like tyrosine kinase-1/placental growth factor or sFLT-1/PlGF ratio). There are currently limited data in pregnant women with CKD. Longitudinal changes of markers inflammation, immunity & angiogenic factors during CKD pregnancy were assessed in this study & their relationship to the development PE explored.


Women with CKD were recruited from a UK renal-obstetric clinic between 2011-2016. Baseline demographics, serial serum samples and pregnancy outcomes were recorded. Samples were analysed for IgG/A/M, high-sensitivity CRP, serum free light chains (sFLC), Beta-2 Microglobulin (B2M), complement factors 3 & 4 (C3/4), uric acid (UA), creatinine, cystatin-C & sFLT-1/PlGF using the Roche Cobas® platform. Gestational periods were split into five groups.


PE was diagnosed in 23% of the 164 pregnancies (136 women) with rates increasing with CKD stage (p=0.011). White ethnicity, non-smoking, SLE, chronic hypertension and previous PE were independent predictors of PE. sFLC, B2M, creatinine, cystatin-C & UA increased significantly over the antenatal period and were higher in the PE group. The greatest predictive accuracy for PE was seen at 16-21 weeks, for sFLC & cystatin-C (AUROC 0.745, 0.810 respectively). Antenatal levels of C3 increased (p<0.001) and IgA fell (p=0.015) more rapidly in the PE vs. non-PE group. The sFlt-1/PlGF ratio was predictive for PE developing at 22-27 weeks gestation (AUROC=0.728, p=0.005) (figure 1).


In women with CKD, an elevated sFLT-1/PlGF ratio is predictive of PE at 22-27 weeks gestation, but not at later gestations. Its predictive accuracy is comparable to markers of kidney function, sFLC and B2M levels.